Evaluating technology under changing financing arrangements.
Changes in health care financing, such as Medicare prospective pricing and Medicaid capitated payment programs, have encouraged medical product industries to provide evidence of new technologies' cost-effectiveness. Health care providers have an equal responsibility to determine the validity of that research.
D003362:Cost-Benefit Analysis; D004345:Drug Industry; D007221:Industry; D012952:Societies; D013673:Technology Assessment, Biomedical / Q000191:economics*; D014481:United States